Courtesy of Apple, most of its chipmaker or designers seem to be having a rough start in 2017. One of these names will have to be the leading American chipmaker, Qualcomm, who Cupertino is presently embroiled in an ongoing patent royalties payment battle with. For those unaware, Apple first took a stand against the chipmaker and lodged a billion lawsuit against them for being charged unfairly …
Just days before a state competition, a transgender Euless Trinity High School wrestler has been put into the middle of a lawsuit …
Mastercard Inc . preyed on more than 46 million unknowing consumers by unfairly charging card fees over a 16-year period, lawyers seeking to bring a 14 billion-pound ($17.2 billion) class-action lawsuit told a London court. The credit-card company infringed European Union competition law by imposing high charges to retailers that accepted its cards between 1992 and 2008, Paul Harris, a lawyer …
In the most recent of three class action lawsuits filed by different plaintiffs attorneys, a California man alleges LG Corp. and Samsung Group engaged in an agreement with each other to provide fixed compensation to their employees to avoid competition. The lawsuit, filed by Andrew Amirnovin in California federal court, also alleges the companies are …
On behalf of a group of more than 40 consumers, a San Francisco law firm is trying to stop a $4 billion merger between Alaska Airlines and Virgin America. The plaintiffs argue the deal would weaken competition in the industry, causing job loss and higher fare prices. Alaska Airlines announced on Aug. 4 that it would acquire Virgin America to create the West Coast’s “premier …
The Department of Justice has filed an antitrust lawsuit against
Deere’s planned purchase of Monsanto’s Precision Planting
business. The lawsuit, filed in a Chicago court, said the deal would remove
competition and raise costs for farmers, Bloomberg reported Wednesday. Deere, which is the world’s largest maker of agricultural
machinery, agreed to buy the unit from Monsanto in November.
The pharmaceutical company allegedly shielded their branded drugs from generic competition and inflated their revenues using a fraudulent scheme. T. Rowe Price also declined to comment. The lawsuit points to Valeant’s alleged decisions to massively increase prices of so-called “orphan drugs” to treat rare medical conditions that face little or no competition and “back door” efforts to receive …